Acute transverse myelitis has been estimated to have an incidence of 1.34 to 4.6 per million.
from the Northern California Kaiser system, this rate was reportedly much higher at 3.1 per 100,000 patient years.
3 A recent study from New Zealand found the incidence of myelitis to be 24.6 (18.2-31.1, 95% confidence intervals) per million; however, this study included patients who had brain lesions found on magnetic resonance imaging (MRI) consistent with multiple sclerosis (MS) as well as patients presenting with partial myelitis. 4 After excluding patients whose MRI scans were consistent with MS and patients with partial myelitis, the incidence of idiopathic acute transverse myelitis was estimated to be 6.2 (2.9-9.6, 95% confidence intervals) per million. There seems to be no familial or ethnic predisposition for acute transverse myelitis and there is no evidence of geographic variation in its incidence. 5 Two recent studies did find a higher incidence in females, 3, 6 but an important caveat to one of these studies is that the proportion of cases that later were diagnosed as multiple sclerosis (MS) was not specified. 3 MS is known to be more common in women and if a significant proportion of the cases were later diagnosed with MS, this may partially explain the higher incidence rate.
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Based on two older case series of acute transverse myelopathy, it was estimated that approximately one-third of patients recover with little to no sequelae, another one-third retain a moderate degree of residual disability and one-third remain severely disabled. 1, 7, 8 In one of these case series, 17 out of 62 patients failed to improve, including three who died. 1 In a recent large cohort of 170 patients with a hetero-patients with idiopathic transverse myelitis, there was one death and 15 (33%) had a poor outcome with an inability to walk at 3 months of follow-up. 10 Prognostic indicators that may portend a poorer outcome in acute transverse myelitis include rapid progression of symptoms, back pain, and spinal shock, as well as absent central conduction on somatosensory evoked potential testing.
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Clinical Presentations of Acute Transverse Myelopathy
Acute transverse myelopathy can present in a variety of ways and involve pyramidal, sensory, and autonomic dysfunction to varying degrees. The pattern of functional loss can help determine the etiology of the injury. A complete loss of spinal cord function may be due to trauma, an acute compressive lesion (abscess, hematoma or tumor), or an acute necrotizing myelitis. 11 Isolated dorsal column involvement may be associated with Vitamin B 12 deficiency, copper deficiency, and nitrous oxide toxicity (►Fig. 1). 12 In contrast, an anterior spinal cord syndrome with acute flaccid weakness, loss of pain and temperature sensation but preserved dorsal column dysfunction, may be caused by an anterior spinal artery occlusion (►Fig. 2). Isolated tract involvement other than the dorsal columns may suggest a paraneoplastic etiology.
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A central cord lesion can present as pyramidal distribution weakness below the level of the lesion, autonomic dysfunction and spinothalamic deficits and may be due to a syrinx or possibly neuromyelitis optica.
11 Brown-Sequard syndrome is due to a unilateral lesion involving the hemicord that presents as ipsilateral corticospinal and dorsal column dysfunction with contralateral spinothalamic deficits and may be due to MS or a compressive etiology. 11 Another more rare presentation that is suggestive of MS is the sensory "useless hand of Oppenheim" phenomenon. This presents as a functionally useless hand with fairly intact motor function and is usually caused by a lesion in the posterior column of the cervical cord leading to a deafferented hand.
14 Cauda equina syndrome presents as flaccid weakness in the lower extremities (that is often asymmetric at presentation), sensory loss in a nerve root distribution, and possibly autonomic involvement resulting in loss of bowel and bladder control. This syndrome can be caused by a viral or bacterial polyradiculitis, but is often associated with a compressive lesion requiring emergent surgical intervention. A conus medullaris injury presents Figure 1 Vitamin B12 deficiency. A woman presents with tingling and cramping sensations in both arms and legs, and low serum B12. Sagittal (A) and axial (B) T2-weighted magnetic resonance images show well-defined, confluent T2-signal abnormality in the dorsal cervical cord without cord expansion. Figure 2 Anterior spinal artery infarct. This is a 33-year-old woman with acute onset of quadriparesis. Sagittal short T1-inversion recovery (STIR) (A) and fat-suppressed gadolinium-enhanced T1-weighted magnetic resonance images (MRIs) (B) show confluent signal abnormality spanning from C4-T1, without corresponding enhancement. Axial STIR (C) and axial gadolinium-enhanced T1-weighted MRIs (D) show signal largely confined to gray matter, with preservation of the normal flow voids within the codominant vertebral arteries.
as early sphincter dysfunction, sacral sensory loss, and relatively mild motor deficits.
Initial Diagnostic Evaluation
Although the clinical presentation of acute myelopathy will lead the clinician to recognize that the spinal cord has sustained injury, the signs and symptoms of myelopathy do not provide insight into etiology and the differential diagnosis is broad (►Table 1). 
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Once neuroimaging has excluded a compressive etiology, the next step in the diagnostic workup is a lumbar puncture (LP) to determine if there are signs of inflammation within the cerebrospinal fluid (CSF). If the CSF is noninflammatory, then vascular, toxic/metabolic, neurodegenerative, or neoplastic myelopathies become much more likely and the subsequent workup should focus on these etiologies. If the 
Differential Diagnosis of Inflammatory Myelopathies
Transverse myelitis typically presents acutely, however, subacute presentations are also described (►Table 2). 7, 17 In acute transverse myelitis, symptoms typically develop over hours to days and then worsen over days to weeks. The first symptoms are often paresthesias ascending from the feet, or back pain at the level of the myelitis coupled with weakness and sphincter dysfunction. 18 Motor, sensory, and autonomic pathways are injured resulting in weakness and sensory disturbance below the level of the lesion. Autonomic involvement is also common and can manifest as paroxysms of hypertension and sweating, urinary retention, bladder incontinence, and loss of bowel function. 5, 18 The term transverse myelitis is somewhat misleading in that the deficits are not necessarily bilateral.
The term was first used in a case report of myelitis complicating a pneumonia. 19 The addition of the term transverse reflected the common clinical finding that patients reported a "band like" horizontal area of altered sensation on the neck or torso. The most commonly implicated viruses are varicella zoster (VZV), enteroviruses, herpes simplex type-2 (HSV-2), and cytomegalovirus (CMV).
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Similarly, the presence of other findings on general physical examination may suggest a systemic autoimmune disease, such as systemic lupus erythematosus (SLE), Sjögren's syndrome, antiphospholipid antibody syndrome (APLS), sarcoidosis, or mixed connective tissue disease (MCTD). Sign and symptoms of a systemic autoimmune disease include dry eyes, dry mouth, malar or discoid rash, oral or genital ulcers, arthritis, synovitis, Raynaud's phenomenon, sclerodactyly, uveitis, or lung or kidney disease. The association of myelitis with collagen vascular diseases underscores the need for a detailed history and examination (both general and neurologic), including a full review of systems when evaluating a patient with transverse myelitis.
Within demyelinating and inflammatory myelopathies, the differential diagnosis includes MS, neuromyelitis optica (NMO), other systemic inflammatory diseases (SLE, Sjögren's disease, sarcoidosis), idiopathic transverse myelitis, acute disseminated encephalomyelitis, and postvaccinial myelitis.
Neuroimaging
Once the MRI excludes compressive etiology (►Table 1), a closer look at the imaging may further assist in narrowing the differential diagnosis, particularly the appearance and pattern of the lesion(s). ►Table 3 describes the imaging patterns associated with some of the more common causes of acute transverse myelitis. Following review of the spinal imaging, a brain MRI should be performed to determine if other demyelinating lesions within the central nervous system (CNS) are present. 7 Patients with MS and NMO are much more likely to have lesions on the brain MRI. In addition, MS-associated spinal cord lesions tend to be asymmetric, peripherally located within the cord axis and tend to extend over fewer than two spinal cord segments (►Fig. 3). 7, 12 Patients with NMO are more likely to have lesions that extend over three or more spinal cord segments and tend to be centrally located.
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Approximately 25% are associated with cord swelling, 21 and may have patchy gadolinium enhancement (►Fig. 4).
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Cerebrospinal Fluid Studies
CSF is an essential component of the evaluation of every patient with suspected myelitis. After measuring the opening pressure, it is essential that routine CSF studies include cell count with differential, protein, and glucose concentrations. In addition, measurements of intrathecal immunoglobulin synthesis with oligoclonal bands and an IgG index or synthesis rate (►Table 4). This requires drawing a serum sample at the time of the lumbar puncture for comparative analysis of gammaglobulin and should be performed on every patient with suspected myelitis. In addition, cytology for evaluation of neoplasm should be included. The evaluation of common infectious causes of myelitis includes the Venereal Disease Research Laboratory test, and polymerase chain reaction (PCR) studies for VZV, HSV-2, CMV, EBV, West Nile virus, and tuberculosis (►Table 5). In addition, bacterial, fungal, and acetate-free biofiltration cultures should be considered. Lyme disease rarely causes an encephalomyelitis, and more typically causes a lymphocytic meningitis, cranial neuritis, and/or polyradiculitis. One milliliter of acellular supernatant should be sent for interleukin-6 (IL-6; see section on biomarkers). Lastly, several ccs of frozen CSF sample should be reserved for additional PCR studies. As in neuroimaging, certain CSF patterns or findings may be helpful in narrowing the differential diagnosis. A low CSF glucose concentration (less than 60% of serum glucose) generally suggests an infection (fungal, bacterial, or mycobacterial), especially when associated with an elevated CSF white blood cell count (WBC). However, an isolated low CSF glucose concentration can occur in neurosarcoidosis, leptomeningeal carcinomatosis, subarachnoid hemorrhage, and even systemic lupus erythematosus (SLE) with CNS involvement. 23 An elevated protein concentration is the most common CSF abnormality in patients with spinal cord disease and is present in $50% of patients with transverse myelitis. 24 An elevated CSF protein concentration is associated with spinal cord tumors, paraneoplastic myelopathies, radiation myelopathies, vascular malformations, infection, syringomyelia with spinal block, and spinal cord trauma.
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Elevation in the CSF WBC count defines inflammatory myelitis. The WBC differential can be very helpful in understanding whether an infectious or autoimmune process is the etiology. The presence of eosinophils can suggest NMO, 25 parasitic or fungal infection, or the presence of a foreign material, such as surgical hardware following a spinal operation. The presence of neutrophils in the CSF (especially a predominance) is highly suggestive of bacterial or mycobacterial infection, but can also be seen in sarcoidosis, NMO, or other autoimmune causes of transverse myelitis, as well as acute viral infections. 26 The presence of eosinophils in the CSF, >5% neutrophils in the CSF, or a pleocytosis of >50 cells/cm 3 is atypical for MS, and increases the suspicion for other diagnoses. 27 If infection is likely, the use of CSF cultures and PCR analysis is invaluable for identifying the cause. ►Table 5 shows some of the common tests that are sent, including their reported sensitivity and specificity. The presence of two or more OCBs in the CSF that are not found in the corresponding serum sample is considered indicative of intrathecal synthesis of gammaglobulin. OCBs are present in >95% of patients with clinically definite MS, 28 and can be a confirmatory test for this diagnosis once systemic inflammatory and infectious etiologies have been excluded. This is not the case at an initial demyelinating event, otherwise known as clinical isolated syndrome (CIS). When a patient presents with CIS (including a transverse myelitis), the rate of OCB positivity may be closer to 50 to 60%. 29 That being said, although not confirmatory, the presence of OCBs has been shown to confer up to a 1.7 increase in risk of developing clinical definite MS over 4 years (hazard ratio ¼ 1.7; confidence interval ¼ 1.1-2.7) that is independent of the baseline MRI findings. 29 In a study of 112 patients with CIS, the presence of OCBs showed a sensitivity of 81% with a specificity of 43% in predicting conversion to clinically The immunoglobulin G (IgG) index is calculated by the following equation: IgG Index ¼ (CSF IgG/albumin)/(serum IgG/albumin). This ratio generally falls between 0.3 and 0.6 for normal patients depending on the laboratory. Like oligoclonal bands, this test assesses an abnormal intrathecal humoral response. Among MS patients, the IgG index is elevated 70 to 80% of the time.
28 Similar caveats to the interpretation of OCB also hold for interpreting the IgG index. Accurate calculation of the IgG index requires that the CSF sample not be contaminated by a significant amount of blood caused by a traumatic LP. CSF IL-6 has been described as a biomarker to help predict disability in acute transverse myelitis. In a study that examined the CSF from six patients with acute transverse myelitis, all six patients showed a dramatic elevation in IL-6 levels. 34 Furthermore, a strong correlation between CSF IL-6 obtained at the time of acute clinical evaluation and long-term disability was observed.
34 IL-6 levels in peripheral blood mononuclear cells were assessed in a larger cohort (n ¼ 50, 37 with MS and 13 with acute transverse myelitis) and compared with healthy controls (n ¼ 16). Mononuclear cell IL-6 levels were increased in patients with acute transverse myelitis relative to healthy controls and those with MS. 35 Another study found that CSF IL-6 levels in patients with NMO or acute transverse myelitis were significantly higher than those with optic neuritis, MS, and normal controls. 36 Furthermore, the CSF IL-6 levels correlated with disease severity of NMO patients. 36 Taken together, IgG Index 1 mL (and 1 mL of blood) Rate nephelometry 140 As with OCB, a serum sample must accompany the CSF sample. A bloody contamination of CSF due to a traumatic lumbar puncture can significantly elevate the IgG index. these studies demonstrate that IL-6 levels can be very useful for distinguishing inflammatory from noninflammatory myelopathies and may be useful prognostically. For these reasons, CSF IL-6 should be measured in all patients presenting with acute transverse myelitis. Accurate measurement requires that the assessment be made prior to treatment with corticosteroids and that the assay be performed on an acellular CSF supernatant.
Serologic Studies
In the right clinical setting, serologic tests for autoimmune or inflammatory disease can help determine the underlying etiology of acute transverse myelitis. The NMO antibody (also known as anti-aquaporin-4 or NMO IgG) is a specific serum autoantibody that binds to the dominant CNS water channel protein aquaporin-4 (AQP4). The sensitivity of NMOIgG is $70% whereas the specificity approaches 100%. 43 and in paraneoplastic myelopathy.
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One useful application of this assay is to identify patients with a longitudinally extensive myelitis (LETM) who are at risk for recurrent myelitis or optic neuritis. A study of 29 patients found that 38% of patients (n ¼ 11) presenting with a first-ever attack of LETM were seropositive for NMO-IgG. 45 Of the 23 that were followed up for at least one year, 55% (5 of 9) of the seropositive patients experienced a relapse of either transverse myelitis or optic neuritis during the 12-month period following their presenting attack. In contrast, none (0 of 14) of the NMO IgG-seronegative group experienced a second attack of any type over the same follow-up period.
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Another autoimmune associated antibody, the anti-SS-A (Ro) antibody, also was associated with acute transverse myelitis and also has some mild predictive value for a relapsing myelitis course. 46 In a small retrospective study, 10 of 13 patients with recurrent myelitis were seropositive for the anti-SS-A (Ro) antibody, compared with 4 of 12 control patients.
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When evaluating a patient with acute transverse myelitis, it is important to screen for other autoimmune disorders, especially if there are any clinical characteristics present that might suggest another autoimmune disease, such as Sjögren's syndrome (xerostomia, xerophthalmia), antiphospholipid antibody syndrome (history of venous thrombosis or multiple miscarriages), SLE (malar rash, arthritis, pericarditis, anemia, nephropathy), sarcoidosis (uveitis, pulmonary symptoms), or mixed connective tissue disease (arthralgias, malaise, Raynaud's phenomenon, Sjögren's syndrome, sclerodactyly, and myopathy). ►Table 6 lists the common available laboratories and their associated conditions. In addition to these studies, a urinalysis with microscopic analysis for hematuria may also be warranted and depending on the clinical level of suspicion, lip/salivary gland biopsy, chest CT scan with intravenous (IV) contrast agent, and a Schirmer test should be considered.
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From an infectious point of view, the only serologic tests recommended for routine screening are the serum rapid plasma reagin (RPR) and lyme antibodies (in patients with radiculitis) (►Table 4). 
Multiple Sclerosis
Although acute transverse myelitis can be the heralding event of MS, 47 MS typically presents with a partial myelitis (►Fig. 3), meaning that either sensory or motor symptoms will be present and that bowel and bladder function is not compromised at the time of the myelitis. MS myelitis patients are more likely to have asymmetric clinical findings with a particular predilection for dorsal column impairment. Clinical patterns of spinal cord impairment commonly present in MS include the Brown-Sequard syndrome, and the sensory useless hand of Oppenheim as described previously. Although complete versions of these syndromes can occur, more commonly in MS, incomplete versions of these syndromes are found.
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A clinical sign referable to the cervical spinal cord often associated with MS is the Lhermitte symptom: the sensation of paresthesias in the spine or limbs elicited by neck flexion. A Lhermitte symptom is present in $41% of MS patients. 49 This finding is not specific to MS and can be present in compressive as well as inflammatory spinal cord injuries. For example, the Lhermitte symptom was present in 35% of NMO patients.
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Patients presenting with a monofocal, demyelinating syndrome, such as myelitis, whose brain MRI studies show at least one lesion consistent with demyelination have an 82% chance of meeting clinical criteria for MS over the subsequent 20 years compared with 21% of patients whose brain MRI is normal. 47 For patients presenting with acute myelitis, the most recent MS diagnostic criteria according to an international panel require only one additional brain lesion for the dissemination in space criteria and a simultaneous asymptomatic gadolinium-enhancing lesion for the dissemination in time criteria, to establish a diagnosis of clinically definite MS. 51, 52 These studies underscore the importance of obtaining a brain MRI following acute transverse myelitis.
Neuromyelitis Optica
Patients presenting with simultaneous myelitis and optic neuritis should be evaluated for NMO; however, in the case of isolated acute transverse myelitis, some clinical clues can raise suspicion for NMO. Attacks of myelitis in NMO are more severe compared with MS and recovery is less complete.
Furthermore, acute transverse myelitis associated with NMO usually affects bilateral motor and sensory pathways, often with near symmetry because the inflammatory attack affects most of the cross-sectional area of the cord. 50 Radiographically the lesions within the cord are usually longitudinally extensive extending over three or more spinal cord segments and tend to be centrally located (►Fig. 4). 12 Patients with recurrent LETM or recurrent optic neuritis are at risk for developing NMO and comprise an increasingly recognized group with an estimated prevalence as high as 1.5% of patients with demyelinating disorders in a recent retrospective review. 53 These patients are referred to as having an NMO spectrum disorder (NMOSD).
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A history of presentation with intractable hiccups or vomiting should raise suspicion for NMO. In one series, intractable hiccups occurred in 8 of 47 (17%) of cases with NMO compared with none of 130 patients with MS. 54 Another case series described 12 patients whose first symptom of NMO was intractable vomiting. 55 In this series, vomiting persisted for a median of 3 months prior to the onset of optic neuritis or acute transverse myelitis. On imaging, these symptoms are associated with involvement of the medulla oblongata affecting the area postrema and medial and lateral portions of the nucleus tractus solitarius. 55, 56 Hiccups were seen in 23 of 35 patients (66%) and nausea was seen in 28 of 35 patients (80%). Intractable hiccups and nausea may portend a future exacerbation because these symptoms preceded an attack of NMO 54% of the time or accompanied an NMO attack 29% of the time.
54
Another clinical symptom that can help distinguish MS from NMO is the presence of radicular pain, a symptom uncommon in MS that occurs in up to 33% of patients with NMO. 48, 50 Paroxysmal tonic spasms may also suggest NMO because in one series these occurred in 35% of NMO patients during acute attacks of myelitis. 48, 50 However, this symptom is generally associated with central demyelination and also occurs commonly in MS patients.
Idiopathic Acute Transverse Myelitis
In 2002, the Transverse Myelitis Consortium Working Group (TMCWG) proposed diagnostic criteria for idiopathic acute transverse myelitis based on expert opinion. The diagnostic criteria require clinical evidence of bilateral sensory, motor, 7 The intent of these criteria were to identify a relatively homogenous patient cohort for the purposes of forwarding research.
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When the Transverse Myelitis Consortium Working Group (TMCWG) proposed diagnostic criteria are applied to a cohort of patients with acute transverse myelitis, a relatively small proportion of patients meet criteria for idiopathic transverse myelitis. In one cohort of 288 patients with clinically diagnosed acute transverse myelitis, 45 patients (15.6%) met criteria for idiopathic transverse myelitis.
10 Another concern about these criteria is that despite these stringent, diagnostic criteria, some patients still go on to ultimately have another diagnosis. For example, in a retrospective study of 24 patients who met proposed TMCWG diagnostic criteria for acute transverse myelitis, and 21 patients who met diagnostic criteria for possible acute transverse myelitis, five patients (11%) developed MS during a mean follow up of 3.5 years. 58 In contrast, in a population-based study of acute transverse myelitis in New Zealand, 15 idiopathic acute transverse myelitis cases were identified by retrospective chart review using the definition of acute transverse myelitis developed by the TMCWG. 4 None of the 15 patients classified as definite or possible idiopathic acute transverse myelitis developed MS. Anti-AQP4 antibody serologic assessment was not available at the time this cohort was identified.
Systemic Lupus Erythematosus
Transverse myelitis is a rare but serious complication of SLE and has been estimated in rheumatologic reviews to occur in 1 to 2% of patients with SLE. [59] [60] [61] Over the past 10 years, several case series reported lupus patients with myelitis.
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Aside from antinuclear antibodies (ANA), the most frequent antibody association reported with SLE myelitis is the antiphospholipid antibody that is positive in 43 to 73% among patients with myelitis. [60] [61] [62] However, the presence of antiphospholipid antibodies is not overrepresented in SLE patients with myelitis. Thus it is unclear if antiphospholipid antibodies have any pathologic role in SLE myelitis although some authors have speculated that antiphospholipid antibodies could cause venous infarcts resulting in thrombotic SLE myelopathy. In the most recent review of the case report literature of SLE-related myelitis, 22 patients with longitudinally extensive myelitis affecting four or more spinal segments were identified. In 23% of patients, myelitis was the first symptom of SLE. Among this group, 65% (11/17) were seropositive for anti-double-stranded DNA antibodies and 74% (14/19) had low levels of complement, whereas 60% (14/ 19) had both laboratory findings. 62 That myelitis can be a presenting manifestation of SLE was documented in a case series of 15 patients who all had systemic signs of SLE. At presentation only four of the 15 fulfilled the American College of Rheumatology criteria for SLE; however, 12 were confirmed as having SLE at follow-up, and the other three were described as having a "lupus-like disease." 61 In this case series, 54% of patients (6 of 11) were antiphospholipid antibody seropositive and all 15 were positive for ANA.
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The main caveat to interpreting the findings is that none of these case series assessed NMO-IgG antibody status. There is a well-established association between NMO and antibodies associated with SLE. 40, 41 In a recent study including 78 patients with NMO, the ANA was positive in 52.6% of patients (n ¼ 41) and antibodies to extractable nuclear antigens (primarily anti-Ro/SSA and anti-La/SSB) were positive in 16.7% of patients (n ¼ 13). 40,41 A case series evaluating 22 patients with SLE myelitis found that 11 had gray matter involvement, whereas 11 had only white matter involvement. Of those with only white matter involvement, 54.5% (6/11) had an associated optic neuritis and 45.5% (5/11) met criteria for NMO. When the NMO-IgG antibody was tested, five of the 22 patients were seropositive. 63 In addition, 50% (11 of 22) fulfilled criteria for an NMO spectrum disorder defined as a syndrome recognized to have a high risk of conversion to NMO (including recurrent LETM or recurrent optic neuritis).
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Sjögren's Syndrome
The CNS manifestations of Sjögren's syndrome are controversial. In the 1980s, two case series suggested that Sjögren's syndrome could mimic MS. 64, 65 One case series found that 10 of 60 patients with primary progressive MS (PPMS) met criteria for Sjögren's syndrome, suggesting that Sjögren's syndrome might be a mimic for PPMS. 66 This hypothesis later was challenged by the observation that in large MS datasets Sjögren's syndrome was not found. [67] [68] [69] A recent review of CNS manifestations of primary Sjögren's syndrome found that the reported prevalence ranges between 0 and 62%.
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The association between Sjögren's syndrome and myelopathy is clearer. A recent large case series of 82 patients found that 35% (29 of 82) had spinal cord involvement. Of these 29, one had a progressive myeloradiculitis, 12 had acute transverse myelitis, and 18 had a chronic myelopathy that mimicked PPMS in 13 patients. 71 Of the 12 patients who had acute transverse myelitis, two also had a concomitant optic neuritis suggesting NMO. Similar to the SLE myelitis literature, most case series of Sjögren's syndrome myelopathy did not test for the NMO IgG. Although the association between primary Sjögren's syndrome and MS remains unclear, there is a definite association between Sjögren's syndrome and NMO. 40,41,72-74 As mentioned above in the SLE section, of 78 patients with NMO, 78% were seropositive for NMO-IgG (n ¼ 61), and of these, 3% met the international criteria for the diagnosis of SLE or Sjögren's syndrome. 40 Also, 53% were seropositive for ANA and 17% were positive for antibodies to extractable nuclear antigens (primarily anti-Ro/SSA and antiLa/SSB).
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Sarcoidosis
The largest review of sarcoidosis included 5092 cases reported in the medical literature from 1941-1972. Within this group, the incidence of CNS involvement in sarcoidosis was estimated to be $5% of cases. 75 In this review only 17 patients of the 5092 (0.3%) had spinal cord involvement. This review was conducted prior to the MRI era. In a more recent series of 2894 patients with systemic sarcoidosis from the Mayo Clinic, 83 (2.9%) were found to have neurologic involvement.
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Within this subset, 18% (15 of 83 patients) presented with myelopathy (0.5% overall; 15 of 2894). The most common presentation was chronic meningitis in 65% (54 of 83) of patients; thus, it is not surprising that the most common finding on MRI was leptomeningeal enhancement (►Fig. 5).
Of the patients with myelopathy, 63% had an abnormal MRI with the typical pattern of linear T2 signal abnormality and patchy enhancement. Additional radiographic features include subpial enhancement, enhancement and thickening of the cauda equina, and enlargement of the spinal cord with T2 hyperintensity but without enhancement (►Fig. 5). 76 Two recent smaller case series supported these findings with 13 to 18% of neurosarcoidosis patients experiencing myelopathy. In both of these case series, the most commonly affected cranial nerve was the optic nerve, which was affected in 25 to 35% of patients.
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If neurosarcoidosis is suspected, plain films of the chest may be useful because in these two recent case series, 50 to 60% of patients had chest x-ray findings suggestive of pulmonary or mediastinal sarcoid. 77, 78 There is evidence that a chest CT is superior to plain films at detecting pulmonary disease (especially mediastinal adenopathy and parenchymal infiltration), 79,80 but a chest x-ray is still the screening imaging study of choice. 80 In the largest case series of spinal cord sarcoidosis to date, 55% (n ¼ 17) had abnormal findings on their initial chest x-rays. 81 An additional seven patients had abnormal results on bronchial alveolar lavage despite normal chest x-ray and high-resolution chest CT studies. Only 11 patients had a gallium scan, and 45% (n ¼ 5) had abnormal results. Lastly, on spinal cord MRI, this group showed various patterns of involvement (anterior, posterior, lateral, and panmedullar), but the most common pattern was central cord (62%; 13 of 21 patients).
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Additional tests that may help identify sarcoidosis include 18 F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) scans, 67 Ga scintigraphy (gallium) scans, serum and CSF angiotensin converting enzyme (ACE), the Kveim-Siltzbach test, and 24-hour urine calcium. A recent study of 20 patients with sarcoidosis tested the sensitivity of 18 F-FDG PET/CT scan versus gallium scan at identifying biopsy proven sites of active sarcoidosis. Overall, gallium scans were 58% sensitive at identifying these sites compared with 79% sensitivity with the 18 F-FDG PET/CT scan. 82 Serum ACE is a very commonly used study to evaluate for the presence of sarcoidosis and has relatively good specificity at 80 to 95%; however, the sensitivity is $60%. 83, 84 The use of CSF ACE to diagnose neurosarcoidosis is controversial, but may be of some use. A study found that CSF ACE levels are insensitive (24-55%) for the diagnosis of CNS sarcoidosis, but if elevated, may be relatively specific (94-95%). 85 The Kveim-Siltzbach test involves injecting part of a spleen from a patient with known sarcoidosis into the skin of a patient with suspected sarcoidosis. If granulomas form within 4 to 6 weeks, the test is positive. The Kveim-Siltzbach test is rarely used in the diagnosis of sarcoidosis anymore, but does have a reported sensitivity of $78%. 86 Lastly, serum hypercalcemia has been reported in as many at 63% of patients with sarcoidosis, but is likely to be closer to 10% with hypercalciuria being about three times more common.
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Postvaccinal and Acute Disseminated Encephalomyelitis
A recent review identified 37 cases of myelitis thought to be caused by an antecedent vaccination. 88 Among these cases, 73% occurred during the first month postvaccination. The cases included 18 children (age 0-18) and 19 adults, with an average age of 24.5 years old. The vaccines that were associated with myelitis were as follows: anti-HBV (13 cases), MMR (six cases), diphtheria-tetanus-pertussis or diphtheria-tetanus (four cases), rabies vaccine (four cases), oral polio virus (three cases), influenza (two cases), and one case each for typhoid vaccine, pertussis, and Japanese B encephalitis. Two cases were after multiple vaccine regimens. 88 Although it is tempting to speculate that vaccination can trigger myelitis, case reports cannot establish a cause-effect relationship. To date, no study has shown an increased incidence of myelitis in Figure 5 Sarcoidosis. Sagittal (A) and axial (B) gadolinium-enhanced T1-weighted magnetic resonance images in a man with gradual onset of weakness in both lower extremities and inflammatory cerebrospinal fluid. Note extensive nodular enhancement along the terminal cord and nerve roots of the cauda equina, consistent with sarcoid granulomatous disease in this patient with longstanding pulmonary sarcoidosis.
those receiving vaccinations; therefore, based on the available data the proposed association between vaccination and myelitis is most likely coincidental. Acute disseminated encephalomyelitis (ADEM) is an uncommon inflammatory disorder of the CNS characterized by widespread demyelination that is often associated with an antecedent infection or vaccination. 22 Symptoms usually develop within 3 weeks following a prodromal phase of fever, myalgia, and malaise. One case series identified a preceding infection or vaccination in 70% of cases within the previous few weeks. 89 In that same series, spinal cord involvement was reported as the presenting symptom in 24% of patients and vaccinations were associated with 12% (10/84) of the cases. Of these 10 patients with ADEM, seven had received a measles vaccination (8%) and three had received pertussis vaccination (3.5%). 89 Postvaccination ADEM has been associated with several vaccines, including rabies, diphtheria-tetanus-polio, smallpox, mumps, rubella, Japanese B encephalitis, pertussis, influenza, hepatitis B, H1N1, and human papillomavirus (HPV). [90] [91] [92] As with myelitis, the possible cause-effect association of ADEM with these various vaccinations, although commonly assumed, is speculative because an increased risk of ADEM following vaccination has not been conclusively demonstrated by prospective observational studies.
Lyme Myelitis
Assessment for Lyme disease is warranted in cases of myelitis occurring in endemic areas. The lymphocytic meningoradiculitis described by Garin, Bujadoux, and Bannwarth 93-95 is a familiar manifestation of the second stage of Lyme disease and is characterized by a painful, ascending polyradiculitis. An acute myelopathy may evolve from these cases.
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Lyme disease presenting as ATM is relatively rare. Lastly, if a comprehensive evaluation fails to identify an anatomic or physiologic correlate for the apparent myelopathy, especially if there are unexpected discrepancies present on the neurologic examination, psychogenic etiologies should be considered.
Initial Treatment
The initial treatment of acute transverse myelitis is determined by the presenting clinical symptoms, the appearance on MRI and the findings on CSF. Once an inflammatory etiology is identified by CSF analysis, the clinician must decide whether or not infection is a likely etiology. Any systemic symptoms suggestive of infection must prompt a thorough infectious workup (fever, chills, rash, etc.). If the CSF shows an elevated WBC count with a neutrophilic predominance, decreased glucose, and elevated protein concentrations, then the indicated cultures and serologies (►Table 4) should be sent and appropriate antibiotic or antiviral agents should be started as soon as possible. There is evidence that empiric corticosteroids may be of benefit in bacterial 109 and tuberculous meningitis, 110 and systemic corticosteroids have been used in a variety of systemic infections and been shown to be safe when used in tandem with empiric antibiotics.
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If the clinical symptoms, CSF profile, and appearance on MRI are indicative of an autoimmune or inflammatory myelitis, serologies looking for systemic autoimmune or inflammatory diseases should be obtained and IV corticosteroids initiated. Although corticosteroid treatment is clearly warranted in the setting of MS and NMO-associated myelitis, not all studies have found a benefit of IV corticosteroids for all causes of myelitis. 112, 113 A study in sarcoidosis 81 and several small studies in pediatric patients found improved outcomes 
61,124
Conclusions
The term acute transverse myelitis was initially applied to idiopathic cases. Acute transverse myelitis is now recognized as a clinical syndrome associated with multiple etiologies.
22
Idiopathic transverse myelitis remains the default diagnosis for unexplained noncompressive myelopathy with radiographic or imaging evidence of inflammation. In a recent large case series of 170 patients presenting with acute noncompressive myelopathy, 40.6% (69/170) of patients had an identifiable cause on initial evaluation; however, on followup, an etiology was secured in 71.2% (121/170) of cases (mean follow-up of 73.2 months). The most commonly identified causes were demyelinating disease (MS 27%, NMO 6%), infarction (15%), parainfectious myelitis (12%), and systemic inflammatory disease (8%, e.g., SLE and Sjögren's syndrome).
9
Determining the etiology of transverse myelitis can be challenging. Effective interpretation of clinical symptoms and signs, high quality neuroimaging and biomarkers such as CSF IL-6 levels and the NMO-IgG can help identify the cause of the myelitis, and guide treatment. In the absence of a definitive diagnosis empiric treatment with IV corticosteroids, plasma exchange, and possibly immune suppression may be warranted. Validated diagnostic criteria, biomarkers, and improved imaging will enhance study of acute transverse myelitis, its idiopathic form, and its associated causes. 57 Hopefully, with improved understanding of acute transverse myelitis, treatments tailored to the underlying disease can be developed.
